Scientists discover urinary biomarker that may help track ALS

March 22, 2017

A study in Neurology suggests that analyzing levels of the protein p75ECD in urine samples from people with amyotrophic lateral sclerosis (ALS) may help monitor disease progression as well as determine the effectiveness of therapies. The study was supported by National Institute of Neurological Disorders and Stroke (NINDS) and National Center for Advancing Translational Sciences (NCATS), both part of the National Institutes of Health.

Mary-Louise Rogers, Ph.D., senior research fellow at Flinders University in Adelaide, Australia, and Michael Benatar, M.D., Ph.D, professor of neurology at the University of Miami, and their teams, discovered that levels of urinary p75 ECD increased gradually in patients with ALS as their disease progressed over a 2-year study period.

"It was encouraging to see changes in p75ECD over the course of the study, because it suggests an objective new method for tracking the progression of this aggressive disease," said Amelie Gubitz, Ph.D., program director at NINDS. "In addition, it indicates the possibility of assessing whether levels of that protein decrease while patients try future treatments, to tell us whether the therapies are having any beneficial effects."

Further analysis of the samples from 54 patients revealed that those who began the study with lower levels of urinary p75ECD survived longer than did patients who had higher levels of the protein initially, suggesting that it could be a prognostic marker of the disease and may inform patients about their illness. Dr. Benatar and his team noted that this may be useful in selecting participants for clinical trials and in improving study design.

The protein p75 is important early in life, but does not appear in adults unless motor neurons are injured. Previous studies in mouse models of ALS reported that p75 was re-expressed in motor neurons as the animals became sick and p75ECD was found in the urine of the mice even before they exhibited muscle weakness. p75 has also been seen on in post-mortem tissue from ALS .

"As we move potential new therapies into phase-2 , our findings suggest that p75ECD may tell us a lot about how well the treatments are working. Additionally, the ease of obtaining could help reduce the burden of patient participation in clinical studies," said Dr. Benatar.

Explore further: World-first way to fast-track drugs for killer disease

More information: Shepheard SR et al. Urinary p75ECD: A prognostic, disease progression, and pharmacodynamics biomarker in ALS. Neurology. February 22, 2017. www.ncbi.nlm.nih.gov/pubmed/28228570

Related Stories

World-first way to fast-track drugs for killer disease

February 23, 2017
Flinders University researchers are pioneering a new and simple test to pick up signals of Motor Neuron Disease in patients.

Parkinson's disease biomarker found in patient urine samples

July 5, 2016
For more than five years, urine and cerebral-spinal fluid samples from patients with Parkinson's disease have been locked in freezers in the NINDS National Repository, stored with the expectation they might someday help unravel ...

Scientists discover protective molecule against Alzheimer's Disease

April 29, 2015
South Australian and Chinese scientists have made a molecular discovery through their research into finding a cure for Alzheimer's Disease.

Protein test is first to predict rate of progression in Lou Gehrig's disease

November 19, 2012
(Medical Xpress)—A novel test that measures proteins from nerve damage that are deposited in blood and spinal fluid reveals the rate of progression of amyotrophic lateral sclerosis (ALS) in patients, according to researchers ...

Simple urine test for motor neurone disease

September 21, 2016
A researcher at Flinders University has developed a simple urine test that gives a quantitative measure of the severity of motor neurone disease.

Study identifies new biomarkers for Huntington's disease

November 7, 2016
Researchers at Stanford University School of Medicine have identified several new biological markers to measure the progression of the inherited neurodegenerative disorder Huntington's disease (HD). Their findings, which ...

Recommended for you

Little understood cell helps mice see color

December 14, 2017
Researchers at the University of Colorado Anschutz Medical Campus have discovered that color vision in mice is far more complex than originally thought, opening the door to experiments that could potentially lead to new treatments ...

Scientists chart how brain signals connect to neurons

December 14, 2017
Scientists at Johns Hopkins have used supercomputers to create an atomic scale map that tracks how the signaling chemical glutamate binds to a neuron in the brain. The findings, say the scientists, shed light on the dynamic ...

Journaling inspires altruism through an attitude of gratitude

December 14, 2017
Gratitude does more than help maintain good health. New research at the University of Oregon finds that regularly noting feelings of gratitude in a journal leads to increased altruism.

Activating MSc glutamatergic neurons found to cause mice to eat less

December 13, 2017
(Medical Xpress)—A trio of researchers working at the State University of New York has found that artificially stimulating neurons that exist in the medial septal complex in mouse brains caused test mice to eat less. In ...

Gene mutation causes low sensitivity to pain

December 13, 2017
A UCL-led research team has identified a rare mutation that causes one family to have unusually low sensitivity to pain.

Scientists discover blood sample detection method for multiple sclerosis

December 13, 2017
A method for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research team.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.